The MDR.AX stock trades at A$0.022 in the pre-market on 01 Apr 2026, setting up a classic oversold bounce scenario for active ASX traders. MedAdvisor Limited (MDR.AX) has fallen 90.43% YTD and sits well below its 50-day and 200-day averages, creating a low-risk entry for short-term bounce plays. Volume is light at 59,301 shares versus an average of 1,383,220, so any uptick in liquidity could trigger a sharp move. We review technicals, fundamentals, Meyka AI signals and price targets for traders watching MDR.AX stock.
MDR.AX stock snapshot and recent price action
MedAdvisor Limited (MDR.AX) opened at A$0.021 and is quoted at A$0.022 pre-market on the ASX. The stock’s day range is A$0.020–A$0.022 and the market capitalisation is A$14,003,474. Year-to-date the share price is down 90.43%, while the 3-month change is -46.34%, showing sustained selling pressure. Liquidity is thin with a last volume of 59,301 versus an average daily volume of 1,383,220, which raises execution and volatility risks for larger orders.
MDR.AX stock technicals and oversold bounce signals
Price sits below the 50-day average (≈ A$0.028) and the 200-day average (≈ A$0.067), a sign the stock is heavily oversold. The 3-month decline and low relative volume create conditions where a modest volume spike often leads to a bounce. Relative indicators reported are sparse, but the key setup is simple: price support near A$0.019–A$0.020 and immediate resistance at recent intraday highs. For an oversold bounce trade, watch for volume above 200,000 shares and a close above A$0.030 to confirm momentum.
MDR.AX stock fundamentals and valuation
MedAdvisor’s reported EPS is -0.11 and PE stands at -0.20, reflecting ongoing losses. Key valuation ratios show price-to-sales at 0.22 and EV-to-sales at 0.33, implying low market pricing relative to revenue. Cash per share is A$0.0173 and operating cashflow per share is -A$0.0242, signalling stretched cash conversion. Revenue growth was positive at 24.64% in the last full year, but margins remain negative and shareholders face dilution and liquidity risk.
Meyka AI rate and MDR.AX stock forecast
Meyka AI rates MDR.AX with a score out of 100: 69.18 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a short-term target of A$0.035 and a 12-month base case of A$0.060 versus the current A$0.022. The implied near-term upside to A$0.035 is 59.09%, and the 12-month upside to A$0.060 is 172.73%. Forecasts are model-based projections and not guarantees.
Sector context, catalysts and key risks for MDR.AX stock
MedAdvisor sits in the Healthcare software niche within the ASX healthcare sector, which trades richer on average than MDR.AX. Catalysts that could drive a bounce include improved earnings, new contract wins, or adoption of the GuildCare and THRiV platforms. Major risks are thin liquidity, continued operating losses, and capital raisings that dilute shareholders. Given sector averages, MDR.AX’s negative margins and limited cash mean any bounce needs verification by volume and news.
Trading plan for an oversold bounce on MDR.AX stock
For traders using an oversold bounce strategy, risk control is crucial with MDR.AX stock. Consider a staged entry and set a hard stop near A$0.015 to limit downside. Scale out increments at A$0.035 and A$0.060 if volume confirms the move. Monitor the earnings calendar and any ASX announcements. Keep position sizes small because average daily liquidity and high share count of 636,521,545 can widen spreads quickly.
Final Thoughts
MDR.AX stock shows the textbook traits of an oversold bounce candidate: a deep decline, price below moving averages, and low liquidity that can magnify moves. MedAdvisor (MDR.AX) is priced at A$0.022 with EPS -0.11 and market cap A$14,003,474, so fundamentals remain weak despite recent revenue growth. Meyka AI’s model projects a near-term bounce to A$0.035 (+59.09%) and a 12-month base case of A$0.060 (+172.73%), while a failure to hold support risks a drop toward A$0.015 (-31.82%). Traders should treat MDR.AX as a high-risk, high-volatility trade and use tight stops, small sizes, and volume confirmation before adding exposure. Meyka AI provides this as AI-powered market analysis; forecasts are model projections and not guarantees.
FAQs
Is MDR.AX stock a buy after the recent fall?
MDR.AX stock is a high-risk setup after heavy losses. Traders may consider small, tactical entries on volume confirmation. Long-term investors should wait for consistent profitability and clearer cash metrics before buying.
What are realistic price targets for MDR.AX stock?
Meyka AI’s near-term target is A$0.035 and a 12-month base case is A$0.060. These imply +59.09% and +172.73% from A$0.022. Forecasts are model-based and not guarantees.
What key indicator confirms an oversold bounce in MDR.AX stock?
For MDR.AX stock, a reliable confirmation is a volume spike above 200,000 shares combined with a daily close above A$0.030. That pairing signals renewed buyer interest and momentum.
How does sector performance affect MDR.AX stock?
Healthcare software on the ASX trades at higher multiples than MDR.AX. Strong sector flows can help lift MDR.AX, but the company must show margin improvement to sustain gains.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)